Huang Xiaoping, Wei Qingzhu, Liu Jianghuan, Niu Hongling, Xiao Gang, Liu Lixin
Department of General Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China.
Department of Pathology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong 510630, P.R. China.
Oncol Lett. 2017 Dec;14(6):7304-7310. doi: 10.3892/ol.2017.7161. Epub 2017 Oct 10.
Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is an oncofetal protein upregulated in tumor cells during carcinogenesis. The aim of the present study was to investigate the expression status of IMP3 in colorectal cancer (CRC) tissues and its clinical significance. Immunostaining was performed in 130 CRC samples, the association of IMP3 expression with clinicopathological characteristics was assessed and 58 patients were selected for survival analysis. To the best of our knowledge, the present study describes for the first time the expression of IMP3 in tumor stromal components of CRC. Stromal expression of IMP3 was detected in 24/130 (18.5%) CRC tissue specimens and was associated with tumor-node-metastasis (TNM) stage (stage III-IV, P=0.003), lymph node metastasis (P=0.006), lympho-vascular invasion (P=0.003), tumor border (P=0.013). Tumoral expression of IMP3 was detected in 94/130 (72.3%) of CRC specimens and was associated with T classification (T3-T4, P=0.027), tumor-node-metastasis (TNM) stage (stage III-IV, P=0.011), lymph node metastasis (P=0.048), tumor budding (>10 buds, P=0.005). Further study indicated that patients with IMP3 expressed in tumor cells and tumor stroma tend to have poorer overall survival rates (P=0.02 and P=0.06, respectively). Moreover, tumoral expression of IMP3 and TNM stage were identified to be independent prognostic factors in CRC. IMP3 was not only expressed in tumor cells but also in stroma cells. Stromal expression of IMP3 was associated with lymph node metastasis and advanced tumor TNM stage. Moreover, the survival analysis indicated that there is a significant association between IMP3 expression in tumor cells and a poorer overall survival rate in patients with CRC. The expression of IMP3 maybe a predicted factor for CRC patient.
胰岛素样生长因子II mRNA结合蛋白3（IMP3）是一种癌胚蛋白，在肿瘤发生过程中在肿瘤细胞中上调。本研究的目的是调查IMP3在结直肠癌（CRC）组织中的表达状况及其临床意义。对130例CRC样本进行免疫染色，评估IMP3表达与临床病理特征的相关性，并选择58例患者进行生存分析。据我们所知，本研究首次描述了IMP3在CRC肿瘤基质成分中的表达。在130例CRC组织标本中的24例（18.5%）检测到IMP3的基质表达，其与肿瘤-淋巴结-转移（TNM）分期（III-IV期，P=0.003）、淋巴结转移（P=0.006）、淋巴管侵犯（P=0.003）、肿瘤边界（P=0.013）相关。在130例CRC标本中的94例（72.3%）检测到IMP3的肿瘤表达，其与T分级（T3-T4，P=0.027）、肿瘤-淋巴结-转移（TNM）分期（III-IV期，P=0.011）、淋巴结转移（P=0.048）、肿瘤芽生（>10个芽，P=0.005）相关。进一步研究表明，IMP3在肿瘤细胞和肿瘤基质中均表达的患者总体生存率往往较低（分别为P=0.02和P=0.06）。此外，IMP3的肿瘤表达和TNM分期被确定为CRC的独立预后因素。IMP3不仅在肿瘤细胞中表达，也在基质细胞中表达。IMP3的基质表达与淋巴结转移和晚期肿瘤TNM分期相关。此外，生存分析表明，CRC患者肿瘤细胞中IMP3表达与较差的总体生存率之间存在显著关联。IMP3的表达可能是CRC患者的一个预测因素。
